Diagnostics of the cardio-toxic effects of oncology therapies
Roman Podoba 1, 2, Anton Lacko 1, 3, Ján Straka 1, 3, Lukáš Zachar 1
1 Catholic University in Ružomberok, Faculty of Health, Ružomberok, Slovak Republic
2 Central Military Hospital SNP in Ružomberok, Department of Radiation and Clinical Oncology, Ružomberok, Slovak Republic
3 Central Military Hospital SNP in Ružomberok, Department of Nuclear Medicine, Ružomberok, Slovak Republic
Korespondenční autor: Roman Podoba (podobar@uvn.sk)
ISSN 1804-7181 (On-line)
Full verze:
Submitted:23. 11. 2016
Accepted: 6. 1. 2017
Published online: 24. 6. 2017
Summary
Despite the rising trend of cancer disease incidence more and more patients succeed in their fight with the disease. Innovative drugs bring cures or at least improvements to the patient’s quality of life. Extensive application of anticancer therapy however brings about the increase of adverse effects of the therapy. Toxic damage of the myocardium remains one of the severest organ damage types with life-threatening consequences. In the last decade, in addition to the known cardio toxicity of traditional cytostatics, specialists have more and more often been facing cardio toxicity caused by targeted oncology therapies. As myocardium damage is hard to treat when the stage of clinical symptoms is reached, emphasis is laid on the timely diagnosing of this drug-related damage. Diagnostic procedures have been introduced for early detection of risk patients before the therapy has even commenced. Timely diagnosis of myocardium effects in the course of the conservative cancer therapy allows for adjustment of the oncology therapy and lifestyle and timely commencement of treatment of the affected myocardium. Echocardiograph is considered the basic procedure of patient monitoring during cancer therapy. MRI of the myocardium and CT cardiograph are limited by price and availability despite their uncontentious role in oncocardiology. Radionuclide ventriculography is considered the gold standard of assessment of the left ventricle function. It is well reproducible and widely available in oncology centres. Laboratory diagnostics of toxic damage of the myocardium focuses on cardinal troponins and natriuretic peptides. This examination performance in clinical practice is undemanding and its application in oncology practice increases.
Keywords: anticancer therapy; cardiotoxicity; diagnostics
Literatura
1. An MM, Zou Z, Shen H, Liu P, Chen ML, Cao YB, Jiang YY (2010). Incidence and risk of significantly raised blood pressure in cancer patients treated with bevacizumab: an updated meta-analysis. Eur J Clin Pharmacol. 66/ 8: 813–821.
2. Atallah E, Durand J, Kantarjian H, Cortes J (2007). Congestive heart failure is a rare event in patients receiving imatinib therapy. Blood. 110/4: 1233–1237.
3. Azim H, Azim HA, Jr., Escudier B (2009). Trastuzumab versus lapatinib: the cardiac side of the story. Cancer Treat Rev. 35/7: 633–638.
4. Bello CL, Mulay M, Huang X, Patyna S, Dinolfo M, Levine S et al (2009). Electrocardiographic characterization of the QTc interval in patients with advanced solid tumors: pharmacokinetic – pharmacodynamic evaluation of sunitinib. Clin Cancer Res. 15/22: 7045–7052.
5. Bowles EJ, Wellman R, Feigelson HS, Onitilo AA, Freedman AN, Delate T et al (2012). Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: a retrospective cohort study. J Natl Cancer Inst. 104/17: 1293–1305.
6. Ederhy S, Izzedine H, Massard C, Dufaitre G, Spano JP, Milano G et al (2011). Cardiac side effects of molecular targeted therapies: towards a better dialogue between oncologists and cardiologists. Crit Rev Oncol Hematol. 80/3: 369–379.
7. Elbl L (2002). Poškození srdce protinádorovou léčbou [Heart damage by anti-tumour therapy]. Praha: Grada (Czech).
8. Ewer MS, Lippman SM (2005). Type II chemotherapy-related cardiac dysfunction: Time to recognize a new entity. J Clin Oncol. 23: 2900–2902.
9. Force T, Krause DS, Van Etten RA (2007). Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition. Nat Rev Cancer. 7/5: 332–344.
10. Giordano SH, Booser DJ, Murray JL, Ibrahim NK, Rahman ZU, Valero V et al (2002). A detailed evaluation of cardiac toxicity: a phase II study of doxorubicin and one- or three-hour-infusion paclitaxel in patients with metastatic breast cancer. Clin Cancer Res. 8/11: 3360–3368.
11. Jurga M a kol. (2011). Klinická a radiačná onkológia [Clinical and radiation oncology]. Martin: Osveta, pp. 504–505 (Slovak).
12. Kerkelä R, Grazette L, Yacobi R, Iliescu C, Patten R, Beahm C et al (2006). Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med. 12/8: 908–916.
13. Lacko A, Straka J, Urban M, Hruboň A, Stranovská M, Valko P, Chalachánová I (2011). Je nukleárna kardiológia stále potrebná [Is nuclear cardiology still needed]? Interná medicína 11/10: 426–439 (Slovak).
14. Mladosievičová B (2015a). Kardiotoxicita cytostatistík a cielenej liečby nádorov [Cardiotoxicity of cytostatics and targeted tumour therapy]. Kardiol. Prax. 13/2: 60–64 (Slovak).
15. Mladosievičová B (2015b). Kardiovaskulárne následky rádioterapie onkologického ochorenia – vieme si pomocť? [Cardiovascular consequences of radiotherapy of tumour disease – can we help them?]. Kardiol. Prax. 13/2: 65–69 (Slovak).
16. Mladosievičová B, Rečková M (2013). Kardiotoxicita cielenej liečby nádorov [Cardiotoxicity of targeted tumour therapy]. Onkologia (Bratisl.). 8/1: 10–14 (Slovak).
17. Mladosievičová B et al. (2014). Kardioonkologie [Cardiooncology]. Praha: Grada (Czech).
18. Petráková K (2011). Antracyklíny v léčbě metastatického karcinomu prsu [Anthracyclines in therapy of metastatic breast carcinoma]. Onkologie 5/1: 23–2. (Czech).
19. Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Press M et al (2011). Adjuvant Trastuzumab in HER2 – Positive Breast Cancer. New England Journal of Medicine. 365/14: 1273–1283.
20. Slart RHJA, Tio RA, Elsinga PH, Schwaiger M (Eds) (2015). Autonomic Innervation of the Heart. Berlin: Springer.
21. Tan C, Tasaka H, Yu KP, Murphy ML, Karnofsky DA (1967). Daunomycin, an antitumor antibiotic, in the treatment of neoplastic disease. Clinical evaluation with special reference to childhood leukemia. Cancer. 20/3: 333–353.
22. Unitt C, Montazeri K, Tolaney S, Moslehi J (2014). Cardiology patient page. Breast cancer chemotherapy and your heart. Circulation. 129/25: e680–82.
23. Urbanová D, Mladosievičová B (2010). Úloha vybraných biochemických markerov pri detekcii kardiotoxity u vyliečených detských onkologických pacientov [Role of selected biochemical markers in detection of cardio toxicity in cured paediatric oncology patients]. Onkológie 5/4: 214–218 (Slovak).
24. Von Hoff DD, Layard MW, Basa P, Davis HL, Jr., Von Hoff AL, Rozencweig M, Muggia FM (1979). Risk factors for doxorubicin – induced congestive heart failure. Ann Intern Med. 91/5: 710–717.
25. Yeh ET, Bickford CL (2009). Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management. J Am Coll Cardiol. 53/24: 2231–2247.
